Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study
- PMID: 31016351
- DOI: 10.1007/s00198-019-04975-y
Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study
Abstract
Change in total hip bone mineral density (BMD) provides a robust indication of anti-fracture effect during treatment monitoring in routine clinical practice, whereas spine BMD change is not independently associated with fracture risk.
Purpose: The role of monitoring bone mineral density (BMD) as an indicator of an anti-fracture effect is controversial. Discordance between the spine and hip BMD is common and creates uncertainty in clinical practice.
Methods: Using a population-based BMD Registry for the Province of Manitoba, Canada, we compared change in the spine and hip BMD as an indicator of treatment-related fracture risk reduction. The study cohort included 6093 women age > 40 years initiating osteoporosis treatment with two consecutive dual-energy X-ray absorptiometry (DXA) scans (mean interval 4.7 years). We computed change in the spine, total hip, and femur neck BMD between the first and second DXA scans as categorical (categorized as stable, detectable decrease, or detectable increase) and continuous measures. We modeled time to first incident fracture, ascertained from health services data, using Cox regression adjusted for baseline fracture probability.
Results: During a mean follow-up of 12.1 years, 995 women developed incident major osteoporotic fractures (MOF) including 246 with hip fractures and 301 with clinical vertebral fractures. Women with a detectable decrease in total hip BMD compared with stable BMD experienced an increase in MOF (adjusted hazard ratio [aHR] 1.46, 95% confidence interval [CI] 1.25-1.70) while those with a detectable increase in total hip BMD experienced a decrease in MOF (aHR 0.71, 95% CI 0.61-0.83), and these results were not attenuated when adjusted for change in spine BMD. Similar results were seen for hip and clinical vertebral fracture outcomes, when BMD change was assessed as a continuous measure, and when femur neck BMD monitoring was used instead of total hip BMD monitoring.
Conclusions: Treatment-related increases in total hip BMD are associated with lower MOF, hip, and clinical vertebral fracture risk compared with stable BMD, while BMD decreases are associated with higher fracture risk. In contrast, spine BMD change is not independently associated with fracture risk.
Keywords: Anti-fracture effect; Bone mineral density; Dual-energy x-ray absorptiometry; Osteoporosis.
Similar articles
-
Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice: A Registry-Based Cohort Study.Ann Intern Med. 2016 Oct 4;165(7):465-472. doi: 10.7326/M15-2937. Epub 2016 Jul 19. Ann Intern Med. 2016. PMID: 27428723
-
Fracture prediction from repeat BMD measurements in clinical practice.Osteoporos Int. 2016 Jan;27(1):203-10. doi: 10.1007/s00198-015-3259-y. Epub 2015 Aug 5. Osteoporos Int. 2016. PMID: 26243362
-
Impact of spine-hip discordance on fracture risk assessment and treatment qualification in Canada: the Manitoba BMD registry.Arch Osteoporos. 2020 Jun 8;15(1):85. doi: 10.1007/s11657-020-00763-y. Arch Osteoporos. 2020. PMID: 32514615
-
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.Cochrane Database Syst Rev. 2021 Jul 7;7(7):CD013424. doi: 10.1002/14651858.CD013424.pub2. Cochrane Database Syst Rev. 2021. PMID: 34231877 Free PMC article.
-
Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force.JAMA. 2025 Feb 11;333(6):509-531. doi: 10.1001/jama.2024.21653. JAMA. 2025. PMID: 39808441
Cited by
-
[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].Wien Klin Wochenschr. 2024 Oct;136(Suppl 16):599-668. doi: 10.1007/s00508-024-02441-2. Epub 2024 Oct 2. Wien Klin Wochenschr. 2024. PMID: 39356323 Free PMC article. German.
-
Fracture severity dependence of bone and muscle performance in patients following single or multiple vertebral fractures.Front Endocrinol (Lausanne). 2024 Nov 6;15:1423650. doi: 10.3389/fendo.2024.1423650. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39568809 Free PMC article.
-
Body composition, balance, functional capacity and falls in older women.Aging Clin Exp Res. 2024 Mar 21;36(1):76. doi: 10.1007/s40520-024-02719-5. Aging Clin Exp Res. 2024. PMID: 38512411 Free PMC article. Clinical Trial.
-
Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).J Bone Miner Metab. 2024 May;42(3):382-388. doi: 10.1007/s00774-024-01515-5. Epub 2024 May 16. J Bone Miner Metab. 2024. PMID: 38755328 Free PMC article. Clinical Trial.
-
Positive Effect of Yerba Mate (Ilex paraguariensis) Consumption on Bone Mineral Density in Postmenopausal Women Assessed by Dual Energy X-Ray Absorptiometry-Based 3-Dimensional Modeling.J Bone Metab. 2025 May;32(2):123-132. doi: 10.11005/jbm.24.827. Epub 2025 May 31. J Bone Metab. 2025. PMID: 40537107 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical